Pharmaceuticals

Kidney Fibrosis Treatment Market Revenue Projected To Hit $23.47 Billion By 2030 With 9.5% CAGR

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Kidney Fibrosis Treatment Market During The Forecast Period?

The market for kidney fibrosis treatment has seen significant expansion in recent years. It is projected to grow from $6.06 billion in 2025 to $6.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. This historical development can be attributed to the rising prevalence of chronic kidney disease, the limited effectiveness of conventional therapies, increased usage of ACE inhibitors and ARBs, the escalating healthcare burden from renal failure, and the expansion of nephrology care services.

The kidney fibrosis treatment market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $8.84 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This expansion during the forecast period is primarily attributed to significant advancements in targeted antifibrotic agents, the increasing aging population affected by ckd, the growing adoption of precision medicine in nephrology, escalating investment in renal research, and enhanced diagnostic capabilities for early-stage kidney disease. Key trends expected in this period encompass a heightened focus on antifibrotic drug development, a rising utilization of combination therapies for ckd, increasing research efforts in stem cell and regenerative therapies, the broader deployment of early diagnostic and monitoring tools, and an increase in clinical trials targeting renal fibrosis pathways.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

What Key Drivers Are Fueling The Growth Of The Kidney Fibrosis Treatment Market?

The anticipated expansion of the kidney fibrosis treatment market is linked to the rising incidence of chronic kidney diseases. Chronic Kidney Disease (CKD) involves a progressive decline in renal function, commonly caused by conditions like diabetes or hypertension, leading to the buildup of metabolic waste in the system. A primary factor contributing to the growing occurrence of CKD is the escalating prevalence of diabetes, which harms the kidney’s blood vessels and compromises their filtration capabilities. For individuals with CKD, kidney fibrosis treatment offers benefits by addressing renal tissue scarring, mitigating inflammation, and decelerating the advance of kidney deterioration, thereby sustaining kidney function. As an illustration, data from Hamadan University of Medical Sciences, an Iran-based university, indicates that by July 2025, the global count of new chronic kidney disease diagnoses is projected to ascend to 25.06 million by 2030. Consequently, the expanding occurrence of chronic kidney diseases is stimulating the growth within the kidney fibrosis treatment market.

How Is The Kidney Fibrosis Treatment Market Categorized Across Its Segment Groups?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Which Trends Are Impacting The Progress Of The Kidney Fibrosis Treatment Market?

Leading companies in the kidney fibrosis treatment sector are concentrating on specialized ileal-release immunomodulatory treatments. An example is NEFECON, an oral budesonide capsule with delayed release that specifically targets the distal ileum to regulate gut-associated B-cells and decrease the production of pathogenic IgA, thereby decelerating kidney fibrosis progression in individuals with IgA nephropathy. As an illustration, Everest Medicines, a biopharmaceutical firm based in China, introduced NEFECON in June 2024. This treatment utilizes an enteric-coated, delayed-release design, which helps in minimizing the body’s exposure to systemic steroids. Its mechanism involves targeting mucosal B-cells within the gut, thereby tackling the fundamental cause of IgA nephropathy, and has proven effective in substantially slowing the deterioration of kidney function.

Which Firms Are Influencing Competition In The Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc

Get The Full Kidney Fibrosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Where Is The Kidney Fibrosis Treatment Market Most Concentrated Geographically?

North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Kidney Fibrosis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795